4.2 Article

Macrophage migration inhibitory factor may play a protective role in osteoarthritis

期刊

ARTHRITIS RESEARCH & THERAPY
卷 23, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13075-021-02442-w

关键词

Macrophage migration inhibitory factor; Osteoarthritis; Inflammation; Cytokines

资金

  1. Canadian Institutes of Health Research [132178, 143058, 153298]
  2. Research and Development Corporation of Newfoundland and Labrador [5404.1423.102]
  3. Memorial University of Newfoundland Medical Research Fund

向作者/读者索取更多资源

The study found that MIF expression is lower in osteoarthritis patients, suggesting a potential protective role, serving as a biomarker to differentiate osteoarthritis from other joint disorders.
Background Osteoarthritis (OA) is the most prevalent form of arthritis and the major cause of disability and overall diminution of quality of life in the elderly population. Currently there is no cure for OA, partly due to the large gaps in our understanding of its underlying molecular and cellular mechanisms. Macrophage migration inhibitory factor (MIF) is a procytokine that mediates pleiotropic inflammatory effects in inflammatory diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, data on the role of MIF in OA is limited with conflicting results. We undertook this study to investigate the role of MIF in OA by examining MIF genotype, mRNA expression, and protein levels in the Newfoundland Osteoarthritis Study. Methods One hundred nineteen end-stage knee/hip OA patients, 16 RA patients, and 113 healthy controls were included in the study. Two polymorphisms in the MIF gene, rs755622, and -794 CATT(5-8), were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and PCR followed by automated capillary electrophoresis, respectively. MIF mRNA levels in articular cartilage and subchondral bone were measured by quantitative polymerase chain reaction. Plasma concentrations of MIF, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) were measured by enzyme-linked immunosorbent assay. Results rs755622 and -794 CATT(5-8) genotypes were not associated with MIF mRNA or protein levels or OA (all p >= 0.19). MIF mRNA level in cartilage was lower in OA patients than in controls (p = 0.028) and RA patients (p = 0.004), while the levels in bone were comparable between OA patients and controls (p = 0.165). MIF protein level in plasma was lower in OA patients than in controls (p = 3.01 x 10(-10)), while the levels of TNF-alpha, IL-6 and IL-1 beta in plasma were all significantly higher in OA patients than in controls (all p <= 0.0007). Multivariable logistic regression showed lower MIF and higher IL-1 beta protein levels in plasma were independently associated with OA (OR per SD increase = 0.10 and 8.08; 95% CI = 0.04-0.19 and 4.42-16.82, respectively), but TNF-alpha and IL-6 became non-significant. Conclusions Reduced MIF mRNA and protein expression in OA patients suggested MIF might have a protective role in OA and could serve as a biomarker to differentiate OA from other joint disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据